Login to Your Account

Cell Therapeutics Backpedals Again, Pulls Pixantrone NDA

By By Marie Powers
Staff Writer

Tuesday, January 31, 2012

The cancer candidate pixantrone (Pixuvri) took another detour in its long and tortuous road to seek potential FDA approval as developer Cell Therapeutics Inc. voluntarily withdrew its new drug application (NDA) in relapsed or refractory aggressive non-Hodgkin's lymphoma (NHL) in patients who failed two or more lines of prior therapy.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription